News & Trends - Biotechnology
CSL passes on Novavax, with focus on AstraZeneca vaccine

Biotech News: CSL confirmed that the company does not have the capacity to simultaneously produce AstraZeneca and Novavax COVID-19 vaccines in Australia.
Novavax is now looking for an alternate manufacturing partner locally.
CSL is already under contract to locally make 50 million doses of the AstraZeneca vaccine, and is currently churning out more than a million doses a week.
Australia is relying on deliveries from Pfizer after restricting the use of AstraZeneca vaccine in April in people below 50 years due to rare blood-clotting cases.
In January, the government ordered 51 million doses of Novavax’s vaccine, with the Therapeutic Goods Administration (TGA) allowing the company to apply for provisional registration of the shot.
You may also like Dynamic women awarded for outstanding contributions to the health industry
Novavax has delayed its timeline for ramping up COVID-19 vaccine production, saying it does not expect to seek regulatory authorisation in the United States, Britain and Europe until the third quarter of 2021.
“At this time CSL does not have the capacity to simultaneously manufacture both the AstraZeneca and Novavax vaccines,” a spokesperson said in response to questions by Reuters.
“We remain fully focused on production of the AstraZeneca vaccine,” the spokesperson said, adding that CSL welcomes “discussions with governments as to how we can support Australia’s ongoing vaccination needs.”
News & Trends - MedTech & Diagnostics

Government’s claim of progress in genomics falls flat while it fails to uphold the fundamental rights of Aussies
The government has unveiled Cancer Australia’s National Framework for Genomics in Cancer Control, a strategic plan designed to guide healthcare […]
MoreNews & Trends - Pharmaceuticals

Healthcare sector’s political donations: What to expect ahead of the federal election
Ahead of the upcoming federal election, attention turns to the financial contributions to major political parties. The Australian Electoral Commission’s […]
MoreNews & Trends - Pharmaceuticals

‘Underinvestment in gynae cancer has left critical gaps,’ says ANZGOG Chair
Ovarian cancer is the deadliest women’s cancer, with the latest statistics revealing a five-year survival rate of just 49%. Alarmingly, […]
MoreNews & Trends - MedTech & Diagnostics

Labor’s one-off funding a band aid for public hospitals while private sector left in limbo
The Federal Government has committed a one-off funding boost of $1.7 billion to public hospitals under a one-year extension to […]
More